Thousands of women with ovarian cancer to access groundbreaking new drug with biggest breakthrough in three decades


Date: 22.01.2021

FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status, It was produced by GSK. Company is focused on maximising patient survival through transformational medicines. GSK's pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality.

Thousands of women who have ovarian cancer will now be able to access a groundbreaking new drug, as progress on tackling the common form of the disease reaches its greatest breakthrough in three decades.

Niraparib, which treats patients by blocking cancer cells from repairing themselves, will be accessible to all women who are newly diagnosed with ovarian cancer.

Every day 11 women die from ovarian cancer, with two-thirds diagnosed with the disease once the cancer has already spread, which makes it more difficult to treat and increases the likelihood of it returning.

Ovarian cancer is one of the most common types of cancer in women – with the NHS saying around half of women with the disease will live for at least five years after diagnosis, while around one in three will live at least a decade.


Views: 19

Leave a request

Select option
Thank you, application submitted.